0001104659-26-032077
SEC filingZura Bio Limited reported full year 2025 financial results with net loss of $68.7 million, R&D expenses of $42.1 million, and cash and cash equivalents of $109.4 million as of December 31, 2025, alongside updates on ongoing Phase 2 tibulizumab trials and a February 2026 public offering raising $144 million gross proceeds, extending cash runway through at least end of 2028.